Genmab A/S (GB:0MGB)
LSE:0MGB
0MGB Stock Chart & Stats
kr1757.69
kr20.29(1.27%)
At close: 4:00 PM EST
kr1757.69
kr20.29(1.27%)
Day’s Range― - ―
52-Week Rangekr1,168.50 - kr2,256.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)22.10K
Market Cap
kr107.91B
Enterprise Valuekr63.39B
Total Cash (Recent Filing)kr3.23B
Total Debt (Recent Filing)kr143.00M
Price to Earnings (P/E)126.1
Beta0.87
Next Earnings
May 07, 2026EPS Estimate
10.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.20
Shares Outstanding64,250,725
10 Day Avg. Volume15,262
30 Day Avg. Volume22,097
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,217.29Price Target Upside26.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ReadoutsSeveral late-stage clinical readouts for Epkinly, Rina-S, and the wholly owned head and neck asset Peto could materially boost revenue visibility if they confirm encouraging earlier efficacy signals.
Regulatory Endpoint StrategyDesigning key combination trials with progression-free survival as the primary endpoint reduces reliance on overall survival and may streamline regulatory pathways for approval.
Strategic Acquisitions And Portfolio DiversificationRecent oncology asset acquisitions diversify revenue away from declining royalty streams and establish a credible long-term growth pathway that supports valuation upside.
Bears Say
Clinical Trial Setback And Confirmatory RiskMissing the overall survival endpoint in the second-line monotherapy trial raises regulatory and commercial uncertainty and increases the risk that confirmatory trials will be required to secure approvals.
Competitive PressureEmerging and intensifying competition in frontline and later-line oncology settings could constrain market share and limit peak sales potential for lead programs.
Financial Leverage And Dilution RiskThe recent acquisition increases near-term financial leverage and presents earnings dilution risk, which could pressure the stock if anticipated growth from the deal does not materialize quickly.
Genmab A/S News
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1168.50 and its highest was kr2256.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr107.91B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 07, 2026 which is in 29 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 17, 2026. The company reported kr3.199 earnings per share for the quarter, missing the consensus estimate of kr17.957 by -kr14.758.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 10.83.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 64,250,725 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr3.199 in its last earnings report, missing expectations of kr17.957. Following the earnings report the stock price went up 4.409%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
0MGB Stock 12 Month Forecast
Average Price Target
kr2,217.29
▲(26.15% Upside)
Technical Analysis
Options Prices
Currently, No data available
---